close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

61.99 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Get These 3 Juicy Dividend Yields While They Last
A good strategy for this unprecedented backdrop may be to bunker down with steady dividend paying companies that are likely to trend higher as market conditions improve. Compared to what was available... 
Via MarketBeat
Topics Economy
News headline image
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
News headline image
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
From Bristol Myers Squibb
Via Business Wire
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
From Bristol Myers Squibb
Via Business Wire
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
From Bristol Myers Squibb
Via Business Wire
News headline image
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
From Bristol Myers Squibb
Via Business Wire
News headline image
Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Topics Climate Change
News headline image
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
From Bristol Myers Squibb
Via Business Wire
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30... 
Via FinancialNewsMedia
Topics Death
News headline image
Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
From Bristol Myers Squibb
Via Business Wire
News headline image
New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today